{"id":"short-regimen-of-benznidazole","safety":{"commonSideEffects":[{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Rash / dermatitis"},{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Bone marrow suppression"}]},"_chembl":{"chemblId":"CHEMBL110","moleculeType":"Small molecule","molecularWeight":"260.25"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Benznidazole is activated by parasite enzymes to form reactive intermediates that bind to and damage parasite DNA and proteins, leading to cell death. It is used to treat Chagas disease, a parasitic infection caused by Trypanosoma cruzi. The short regimen formulation aims to improve treatment compliance and reduce cumulative toxicity while maintaining efficacy.","oneSentence":"Benznidazole is a nitroimidazole antiparasitic that generates reactive metabolites to damage the DNA and cellular structures of Trypanosoma cruzi parasites.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:34:25.194Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chagas disease (Trypanosoma cruzi infection) — acute and chronic phases"}]},"trialDetails":[{"nctId":"NCT06339710","phase":"PHASE3","title":"Short Benznidazole Regimen for Chronic Phase Chagas Disease Patients","status":"WITHDRAWN","sponsor":"Evandro Chagas Institute of Clinical Research","startDate":"2025-01-30","conditions":"Chronic Chagas Disease","enrollment":""},{"nctId":"NCT04897516","phase":"PHASE3","title":"Shorter Benznidazole Regimens Compared to the Standard Regimen for Chagas Disease","status":"RECRUITING","sponsor":"Laboratorio Elea Phoenix S.A.","startDate":"2021-07-28","conditions":"Chagas Disease","enrollment":300},{"nctId":"NCT01489228","phase":"PHASE2","title":"Proof-of-Concept Study of E1224 to Treat Adult Patients With Chagas Disease","status":"UNKNOWN","sponsor":"Drugs for Neglected Diseases","startDate":"2011-06","conditions":"Chronic Chagas Disease, Indeterminate","enrollment":230}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Benznidazole 2 weeks"],"phase":"phase_3","status":"active","brandName":"Short regimen of benznidazole","genericName":"Short regimen of benznidazole","companyName":"Laboratorio Elea Phoenix S.A.","companyId":"laboratorio-elea-phoenix-s-a","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Benznidazole is a nitroimidazole antiparasitic that generates reactive metabolites to damage the DNA and cellular structures of Trypanosoma cruzi parasites. Used for Chagas disease (Trypanosoma cruzi infection) — acute and chronic phases.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}